cortodoxone

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: cortodoxone
• 英文别名: 17α,21-Dihydroxypregn-4-en-3,20-dion；(8xi,9xi,10xi,13xi,14xi)-17,21-Dihydroxypregn-4-ene-3,20-dione；(17R)-17-hydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one
• 化学式: C₂₁H₃₀O₄
• mdl: MFCD00377927
• 分子量: 346.467
• InChiKey: WHBHBVVOGNECLV-VLAJLFEZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  25
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.81
• 拓扑面积：
  74.6
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• [EN] C20-C21 SUBSTITUTED GLUCOCORTICOID RECEPTOR AGONISTS<br/>[FR] AGONISTES DU RÉCEPTEUR DE GLUCOCORTICOÏDE SUBSTITUÉS EN C20-C21
  申请人：SCHERING CORP

  公开号：WO2009085879A2

  公开（公告）日：2009-07-09

  The present invention provides compounds of Formula (I), and pharmaceutically acceptable salts, solvates, esters, prodrugs, tautomers, or isomers of said compounds), having general structure (I); wherein L, R1, R2, R3, R4, R5, and R6 are selected independently of each other and as defined herein. The present invention also provides compounds (and salts, solvates, esters, prodrugs, tautomers, and isomers) of Formulas II, III, IV, V, and Vl, as defined herein. Also provided are pharmaceutical compositions, methods of preparing, and methods of using such compounds in the treatment and prophylaxis of a wide range of immune, autoimmune, and inflammatory diseases and conditions.

  本发明提供了具有一般结构（I）的化合物，以及该化合物的药用盐、溶剂合物、酯、前药、互变体或异构体（包括L、R1、R2、R3、R4、R5和R6在内独立选择的定义）。本发明还提供了根据本文所定义的化合物（和盐、溶剂合物、酯、前药、互变体和异构体）的II、III、IV、V和VI式化合物。还提供了药物组合物、制备方法以及利用这些化合物在治疗和预防各种免疫、自身免疫和炎症性疾病和症状中的方法。
• CORTEXOLONE-17-ALPHA-PROPIONATE CRYSTALLINE FORM III AND ITS PHARMACEUTICAL USE
  申请人：Cassiopea S.p.A.

  公开号：EP3521298A1

  公开（公告）日：2019-08-07

  The present invention refers to new crystalline forms of cortexolone 17α-propionate and their pharmaceutical use.

  本发明涉及可的松 17α 丙酸酯的新结晶形式及其制药用途。
• PROCESS FOR THE PREPARATION OF CORTEXOLONE 17 A-PROPIONATE AND NEW HYDRATED CRYSTALLINE FORM THEREOF
  申请人：Farmabios S.p.A.

  公开号：EP4071160A1

  公开（公告）日：2022-10-12

  The present invention is directed to a process for the preparation of cortexolone 17α-propionate, comprising a hydrolysis reaction of an ortho-ester of formula (III) in which R is a hydrogen atom or a methyl group, in the presence of a dilute solution of acetic acid. The present invention is also directed to a hydrated crystalline form of cortexolone 17a-propionate obtained by such process.

  本发明涉及一种制备可的松 17α 丙酸酯的工艺，包括式 (III) 原酯的水解反应 其中 R 是氢原子或甲基、 在稀醋酸溶液存在下进行水解反应。 本发明还涉及通过这种工艺获得的可的松 17a 丙酸酯的水合结晶形式。
• Enzymatic process for obtaining 17 alpha-monoesters of cortexolone and/or its 9,11-dehydroderivatives
  申请人：Cassiopea S.P.A.

  公开号：US10716796B2

  公开（公告）日：2020-07-21

  The present invention refers to a new enzymatic process for obtaining 17α-monoesters of cortexolone and/or its 9,11-dehydroderivatives starting from the corresponding 17α,21-diesters which comprises an enzymatic alcoholysis reaction. Furthermore, the present invention refers to new crystalline forms of cortexolone-17α-propionate and 9,11-dehydro-cortexolone 17α-butanoate.

  本发明是指一种从相应的 17α，21-二酯开始获得可的松酮 17α-单酯和/或其 9，11-脱氢衍生物的酶法新工艺，该工艺包括酶法醇解反应。此外，本发明还涉及可的松酮-17α-丙酸酯和 9,11-脱氢可的松酮-17α-丁酸酯的新结晶形式。
• Enzymatic process for obtaining 17 α-monoesters of cortexolone and/or its 9,11-dehydroderivatives
  申请人：Cassiopea S.P.A.

  公开号：US11207332B2

  公开（公告）日：2021-12-28

  The present invention refers to a new enzymatic process for obtaining 17α-monoesters of cortexolone and/or its 9,11-dehydroderivatives starting from the corresponding 17α,21-diesters which comprises an enzymatic alcoholysis reaction. Furthermore, the present invention refers to new crystalline forms of cortexolone-17α-propionate and 9,11-dehydro-cortexolone 17α-butanoate.

  本发明是指一种从相应的 17α，21-二酯开始获得可的松酮 17α-单酯和/或其 9，11-脱氢衍生物的酶法新工艺，该工艺包括酶法醇解反应。此外，本发明还涉及可的松酮-17α-丙酸酯和 9,11-脱氢可的松酮-17α-丁酸酯的新结晶形式。